Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference

Annovis Bio Inc. (NYSE: ANVS) announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York City. This presentation provides investors and industry stakeholders with critical insights into the company's progress in developing therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD).

The conference appearance is significant as it offers Annovis Bio a platform to showcase its innovative approaches to addressing neurodegeneration, which affects millions globally. Investors will gain updates on clinical trials, regulatory milestones, and strategic directions that could influence stock performance and future funding opportunities. For more details on the announcement, visit https://ibn.fm/bX1aJ.

Annovis Bio's focus on improving patient outcomes and quality of life through novel therapies underscores the importance of this presentation. Neurodegenerative diseases represent a growing healthcare burden, with limited effective treatments available. Advances from companies like Annovis could lead to breakthrough therapies, potentially reducing healthcare costs and enhancing patient care worldwide.

The implications extend beyond immediate investor interest, as successful developments in this field could reshape treatment paradigms and offer hope to patients and families affected by these debilitating conditions. Industry observers will monitor for updates on pipeline progress and partnerships that might emerge from such high-profile events.

For ongoing news and updates related to Annovis Bio, the company maintains a newsroom accessible at https://ibn.fm/ANVS. This resource provides stakeholders with timely information, reinforcing transparency and engagement in the investment community.